JP6648115B2 - 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体 - Google Patents

変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体 Download PDF

Info

Publication number
JP6648115B2
JP6648115B2 JP2017515059A JP2017515059A JP6648115B2 JP 6648115 B2 JP6648115 B2 JP 6648115B2 JP 2017515059 A JP2017515059 A JP 2017515059A JP 2017515059 A JP2017515059 A JP 2017515059A JP 6648115 B2 JP6648115 B2 JP 6648115B2
Authority
JP
Japan
Prior art keywords
oxo
chloro
methyl
amino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528487A (ja
JP2017528487A5 (enExample
Inventor
スーザン アシュウェル，
スーザン アシュウェル，
アン−マリエ キャンベル，
アン−マリエ キャンベル，
ジャスティン アンドリュー カラベラ，
ジャスティン アンドリュー カラベラ，
アール． ブルース ディボールド，
アール． ブルース ディボールド，
アンナ エリクソン，
アンナ エリクソン，
ゲイリー ガスタフソン，
ゲイリー ガスタフソン，
デイビッド アール． ジュニア ランシア，
デイビッド アール． ジュニア ランシア，
ジャン リン，
ジャン リン，
ウェイ ルー，
ウェイ ルー，
ツォングォ ワン，
ツォングォ ワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of JP2017528487A publication Critical patent/JP2017528487A/ja
Publication of JP2017528487A5 publication Critical patent/JP2017528487A5/ja
Application granted granted Critical
Publication of JP6648115B2 publication Critical patent/JP6648115B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017515059A 2014-09-19 2015-09-18 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体 Active JP6648115B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US62/053,006 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US62/128,089 2015-03-04
US201562150812P 2015-04-21 2015-04-21
US62/150,812 2015-04-21
PCT/US2015/051055 WO2016044789A1 (en) 2014-09-19 2015-09-18 Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Publications (3)

Publication Number Publication Date
JP2017528487A JP2017528487A (ja) 2017-09-28
JP2017528487A5 JP2017528487A5 (enExample) 2019-10-10
JP6648115B2 true JP6648115B2 (ja) 2020-02-14

Family

ID=54291606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515059A Active JP6648115B2 (ja) 2014-09-19 2015-09-18 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体

Country Status (37)

Country Link
US (8) US9834539B2 (enExample)
EP (4) EP4257131A3 (enExample)
JP (1) JP6648115B2 (enExample)
KR (1) KR102209667B1 (enExample)
CN (3) CN107001328B (enExample)
AU (3) AU2015317329B2 (enExample)
BR (1) BR112017005238B1 (enExample)
CA (1) CA2961817C (enExample)
CL (1) CL2017000658A1 (enExample)
CO (1) CO2017003241A2 (enExample)
CY (2) CY1121149T1 (enExample)
DK (2) DK3447050T3 (enExample)
EA (1) EA034336B1 (enExample)
EC (1) ECSP17022933A (enExample)
ES (3) ES2790640T3 (enExample)
FI (1) FI3733662T3 (enExample)
HR (1) HRP20200666T1 (enExample)
HU (2) HUE062424T2 (enExample)
IL (3) IL292608B2 (enExample)
LT (2) LT3447050T (enExample)
MA (2) MA53352A (enExample)
ME (1) ME03776B (enExample)
MX (2) MX2017003404A (enExample)
MY (2) MY176250A (enExample)
NZ (1) NZ730373A (enExample)
PE (1) PE20171056A1 (enExample)
PH (1) PH12017500517B1 (enExample)
PL (3) PL3194376T3 (enExample)
PT (3) PT3733662T (enExample)
RS (2) RS60140B1 (enExample)
SA (1) SA517381129B1 (enExample)
SG (1) SG11201702194SA (enExample)
SI (2) SI3194376T1 (enExample)
SM (2) SMT202000212T1 (enExample)
TW (1) TWI686390B (enExample)
WO (1) WO2016044789A1 (enExample)
ZA (3) ZA201702127B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2740424T3 (es) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
EP3064595B1 (en) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
EP3102568B1 (en) 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
KR102209667B1 (ko) * 2014-09-19 2021-01-29 포르마 세라퓨틱스 인크. 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
MX2017003664A (es) 2014-09-19 2017-07-13 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1.
EP3201185B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
AU2015317321B2 (en) * 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
CN107428690B (zh) * 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HUE059057T2 (hu) 2017-05-04 2022-10-28 Bayer Cropscience Ag 2-{[2-(feniloximetil)piridin-5-il]oxi}-etánamin-származékok és rokon vegyületek mint peszticidek, például növényvédelemre
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2020232381A1 (en) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
US11738018B2 (en) 2018-05-16 2023-08-29 FORMA Therapeuetics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US20210196701A1 (en) * 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11497743B2 (en) 2018-05-16 2022-11-15 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
AU2003243497A1 (en) 2002-06-12 2003-12-31 Millennium Pharmaceuticals, Inc. Antagonists of melanin concentrating hormone receptor
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
RU2284325C2 (ru) * 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
CA2657287A1 (en) * 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
EP2152676B1 (en) 2007-04-30 2013-04-03 ProMetic BioSciences Inc. "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives"
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
EP2509600B1 (en) * 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
CN102558049B (zh) 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
AU2012313888B2 (en) 2011-09-27 2016-03-31 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9353121B2 (en) 2011-12-21 2016-05-31 The Regents Of The University Of Colorado, A Body Corporate Anti-cancer compounds targeting Ral GTPases and methods of using the same
LT2800743T (lt) 2012-01-06 2018-06-25 Agios Pharmaceuticals, Inc. Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
BR112015022483A2 (pt) * 2013-03-14 2017-07-18 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
BR112016018604A2 (pt) 2014-02-11 2017-08-08 Bayer Pharma AG Benzimidazol-2-aminas como inibidores de midh1
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
AU2015317321B2 (en) 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
EP3201185B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
KR102209667B1 (ko) * 2014-09-19 2021-01-29 포르마 세라퓨틱스 인크. 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
CN107428690B (zh) 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
JP6473270B2 (ja) 2015-07-27 2019-02-20 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用
WO2017146795A1 (en) 2016-02-26 2017-08-31 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malignancies and solid tumours
ES2814290T3 (es) 2016-06-06 2021-03-26 Lilly Co Eli Inhibidores de IDH1 mutante
WO2017223202A1 (en) 2016-06-22 2017-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer
PH12019501328B1 (en) 2016-12-16 2023-05-12 Lilly Co Eli 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors

Also Published As

Publication number Publication date
CN107001328A (zh) 2017-08-01
AU2021215141B2 (en) 2023-10-19
CN111909130A (zh) 2020-11-10
WO2016044789A1 (en) 2016-03-24
CN117695280A (zh) 2024-03-15
EP3194376B1 (en) 2018-10-24
US20200223822A1 (en) 2020-07-16
DK3194376T3 (en) 2019-01-21
TWI686390B (zh) 2020-03-01
PL3194376T3 (pl) 2019-05-31
SMT201900018T1 (it) 2019-02-28
DK3447050T3 (da) 2020-03-09
EP3194376A1 (en) 2017-07-26
PE20171056A1 (es) 2017-07-21
SA517381129B1 (ar) 2021-04-26
MA53352A (fr) 2021-09-15
NZ730373A (en) 2019-11-29
CY1122865T1 (el) 2021-05-05
EP3733662A1 (en) 2020-11-04
SI3447050T1 (sl) 2020-08-31
MX385512B (es) 2025-03-18
CA2961817C (en) 2024-03-12
IL292608A (en) 2022-07-01
CN111909130B (zh) 2023-10-31
PT3733662T (pt) 2023-08-18
AU2019283765A1 (en) 2020-01-16
BR112017005238A2 (pt) 2017-12-19
NZ758641A (en) 2023-12-22
EP3733662B1 (en) 2023-06-07
PH12017500517B1 (en) 2022-08-03
ES2704897T3 (es) 2019-03-20
ZA201902446B (en) 2023-12-20
EP4257131A2 (en) 2023-10-11
JP2017528487A (ja) 2017-09-28
AU2021215141A1 (en) 2021-09-02
MY197533A (en) 2023-06-21
CA2961817A1 (en) 2016-03-24
IL292608B2 (en) 2024-10-01
EA201790657A1 (ru) 2017-08-31
ES2790640T3 (es) 2020-10-28
US20240150319A1 (en) 2024-05-09
SMT202000212T1 (it) 2020-05-08
LT3447050T (lt) 2020-05-11
EP3447050B1 (en) 2020-02-19
BR112017005238B1 (pt) 2023-01-17
AU2015317329A1 (en) 2017-04-27
SG11201702194SA (en) 2017-04-27
IL251163B (en) 2021-05-31
LT3194376T (lt) 2019-02-25
MX2017003404A (es) 2017-07-28
PL3447050T3 (pl) 2020-07-27
ZA202304409B (en) 2024-08-28
ZA201702127B (en) 2019-06-26
ECSP17022933A (es) 2017-08-31
US20170174658A1 (en) 2017-06-22
US10550098B2 (en) 2020-02-04
US10414752B2 (en) 2019-09-17
SI3194376T1 (sl) 2019-03-29
TW201617335A (zh) 2016-05-16
RS60140B1 (sr) 2020-05-29
KR102209667B1 (ko) 2021-01-29
EP3447050A1 (en) 2019-02-27
PL3733662T3 (pl) 2024-01-22
CL2017000658A1 (es) 2017-12-22
IL282363B (en) 2022-06-01
AU2015317329B2 (en) 2019-10-31
US20160083366A1 (en) 2016-03-24
US20230125739A1 (en) 2023-04-27
HUE041460T2 (hu) 2019-05-28
US20180312487A1 (en) 2018-11-01
CN107001328B (zh) 2020-06-05
HUE062424T2 (hu) 2023-11-28
CO2017003241A2 (es) 2017-09-20
IL292608B1 (en) 2024-06-01
KR20170063742A (ko) 2017-06-08
US20210078973A1 (en) 2021-03-18
ME03776B (me) 2021-04-20
US20190263778A1 (en) 2019-08-29
EA201790657A8 (ru) 2018-02-28
MA40481A (fr) 2017-07-26
EP4257131A3 (en) 2024-01-10
US11498913B2 (en) 2022-11-15
MY176250A (en) 2020-07-24
RS58184B1 (sr) 2019-03-29
US9834539B2 (en) 2017-12-05
US12275715B2 (en) 2025-04-15
EA034336B1 (ru) 2020-01-29
ES2953347T3 (es) 2023-11-10
AU2019283765B2 (en) 2021-05-13
US10889567B2 (en) 2021-01-12
CY1121149T1 (el) 2020-05-29
MX2019013203A (es) 2020-01-20
IL251163A0 (en) 2017-04-30
FI3733662T3 (fi) 2023-08-09
PH12017500517A1 (en) 2017-08-07
PT3447050T (pt) 2020-09-17
IL282363A (en) 2021-06-30
HRP20200666T1 (hr) 2020-07-24
PT3194376T (pt) 2019-02-04

Similar Documents

Publication Publication Date Title
US12275715B2 (en) Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6751081B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
JP6820836B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体
HK40102356A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40033589B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40033589A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40002980B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40002980A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK1241376B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK1241376A1 (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20190603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190606

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200115

R150 Certificate of patent or registration of utility model

Ref document number: 6648115

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250